It is currently trading at $4.60 which is marginally higher than $4.29, the stock’s 50 day moving average and a bit higher than the 200 day moving average of $4.09. The 50 day moving average went up $0.31 or +7.15% whereas the 200 day moving average was up $0.51 or +12.56%. Trading volume for Achillion Pharmaceuticals, Inc. was 797K by the end of trading on Thursday. Shares saw a steep decrease in trading volume of 55.36% under the normal average daily volume.
Investors are a little more bearish on shares of the company of late if you evaluate the motion in short interest. The firm experienced a rise in short interest from June 15, 2017 to May 31, 2017 of 1.98%. Short interest grew from 9,626,831 to 9,817,187 over that timeframe. With short interest at 9,817,187 and short average daily volume at 1,638,039, days to cover is 6.0 and the percentage of shorted shares was 0.07% on May 31.
Here is the rundown on market activity for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Director Jason S. Fisherman disclosed the purchase of 10,000 shares. The shares were bought on December 22nd for an average price of $3.96. Fisherman now owns $198,000 of the stock per the Form 4 SEC filing. Chief Commercial Officer Joseph Truitt bought 3,500 shares at an average price of $4.06 on Fri the 2nd. That brings the Chief Commercial Officer’s holdings to $14,210 per an SEC filing yesterday.
These firms have also modified their investment in ACHN. As of the end of the quarter Creative Planning had bought a total of 254 shares growing its holdings by 0.2%. The value of the investment in Achillion Pharmaceuticals, Inc. went from $655,000 to $715,000 increasing 9.2% since the last quarter. As of quarter end Bank Of Montreal /can/ had acquired 3,410 shares growing its stake by 6.4%. The value of the investment in ACHN increased from $224,000 to $260,000 a change of 16.1% for the reporting period.
Morgan Stanley bolstered its investment by buying 1,247 shares an increase of 98.3% as of 03/31/2017. Morgan Stanley now holds 2,515 shares with a value of $11,000. The value of the position overall is up by 120.0%. As of the end of the quarter Goldman Sachs Group Inc had sold 695,078 shares trimming its position 97.8%. The value of the total investment in Achillion Pharmaceuticals, Inc. decreased from $2,935,000 to $65,000 a change of $2,870,000 quarter to quarter.
On May 18 the stock rating was upgraded from “Market Perform” to “Outperform” in an announcement from Leerink Swann. Equity analyst Chardan Capital raised the price target and upgraded the stock on November 4 changing the price objective from $4.00 to $5.00 and changing the rating from “Sell” to “Neutral”.
On November 4 the company was upgraded to “Neutral” from “Sell” with a current price target of $5.00 in a statement from Chardan Capital. Wedbush began coverage of ACHN setting a rating of “Outperform” and a price target of $13.00.
On September 15, 2016 FBR Capital started coverage by announcing an initial rating of “Outperform”. Equity analyst Chardan Capital added the stock to its research portfolio giving it an initial rating of “Sell” and projecting a price target of $4.00.
The company is up since yesterday’s close of $4.5. As of the latest earnings report the EPS was $-0.47 and is expected to be $-0.64 for the current year with 136,723,000 shares outstanding. Next quarter’s EPS is expected be $-0.18 with next year’s EPS projected to be $-0.09.
Achillion Pharmaceuticals, Inc., launched on August 5, 1998, is a biopharmaceutical company. The Company is involved in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial..